» Articles » PMID: 22293630

A Hexane Fraction of American Ginseng Suppresses Mouse Colitis and Associated Colon Cancer: Anti-inflammatory and Proapoptotic Mechanisms

Overview
Specialty Oncology
Date 2012 Feb 2
PMID 22293630
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Ulcerative colitis is a chronic inflammatory condition associated with a high colon cancer risk. We have previously reported that American ginseng extract significantly reduced the inflammatory parameters of chemically induced colitis. The aim of this study was to further delineate the components of American ginseng that suppress colitis and prevent colon cancer. Among five different fractions of American ginseng (butanol, hexane, ethylacetate, dichloromethane, and water), a hexane fraction has particularly potent antioxidant and proapoptotic properties. The effects of this fraction were shown in a mouse macrophage cell line (ANA-1 cells), in a human lymphoblastoid cell line (TK6), and in an ex vivo model (CD4(+)/CD25(-) primary effector T cells). A key in vivo finding was that compared with the whole American ginseng extract, the hexane fraction of American ginseng was more potent in treating colitis in a dextran sodium sulfate (DSS) mouse model, as well as suppressing azoxymethane/DSS-induced colon cancer. Furthermore, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) labeling of inflammatory cells within the colonic mesenteric lymph nodes was elevated in mice consuming DSS + the hexane fraction of American ginseng. Results are consistent with our in vitro data and with the hypothesis that the hexane fraction of American ginseng has anti-inflammatory properties and drives inflammatory cell apoptosis in vivo, providing a mechanism by which this fraction protects from colitis in this DSS mouse model. This study moves us closer to understanding the molecular components of American ginseng that suppress colitis and prevent colon cancer associated with colitis.

Citing Articles

Pharmacological effects of ginseng and ginsenosides on intestinal inflammation and the immune system.

Zhao L, Zhang T, Zhang K Front Immunol. 2024; 15:1353614.

PMID: 38698858 PMC: 11064651. DOI: 10.3389/fimmu.2024.1353614.


Panaxynol improves crypt and mucosal architecture, suppresses colitis-enriched microbes, and alters the immune response to mitigate colitis.

Bullard B, McDonald S, Cardaci T, VanderVeen B, Mohammed A, Kubinak J Am J Physiol Gastrointest Liver Physiol. 2024; 326(5):G591-G606.

PMID: 38469632 PMC: 11376977. DOI: 10.1152/ajpgi.00004.2024.


Panaxynol alleviates colorectal cancer in a murine model via suppressing macrophages and inflammation.

McDonald S, Bullard B, VanderVeen B, Cardaci T, Huss A, Fan D Am J Physiol Gastrointest Liver Physiol. 2023; 325(4):G318-G333.

PMID: 37489869 PMC: 10642997. DOI: 10.1152/ajpgi.00119.2023.


Pharmacokinetics of Panaxynol in Mice.

Tashkandi H, Chaparala A, Peng S, Nagarkatti M, Nagarkatti P, Chumanevich A J Cancer Sci Clin Ther. 2020; 4(2):133-143.

PMID: 32905447 PMC: 7472592. DOI: 10.26502/jcsct.5079059.


Preventive effects of Korean red ginseng on experimentally induced colitis and colon carcinogenesis.

Shin H, Kim D, Zhong X, Yum H, Kim S, Chun K J Tradit Complement Med. 2020; 10(3):198-206.

PMID: 32670814 PMC: 7340975. DOI: 10.1016/j.jtcme.2020.04.004.


References
1.
Godkin A, De Belder A, Villa L, Wong A, Beesley J, Kane S . Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest. 1996; 26(10):867-72. DOI: 10.1111/j.1365-2362.1996.tb02131.x. View

2.
Choi H, Kim K, Sohn E, Park J, Kim B, Moon E . Red ginseng acidic polysaccharide (RGAP) in combination with IFN-gamma results in enhanced macrophage function through activation of the NF-kappaB pathway. Biosci Biotechnol Biochem. 2008; 72(7):1817-25. DOI: 10.1271/bbb.80085. View

3.
Martin A, Villegas I, La Casa C, Alarcon de la Lastra C . The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol. 2003; 481(2-3):281-91. DOI: 10.1016/j.ejphar.2003.09.033. View

4.
Sanchez-Fidalgo S, Villegas I, Martin A, Sanchez-Hidalgo M, Alarcon de la Lastra C . PARP inhibition reduces acute colonic inflammation in rats. Eur J Pharmacol. 2007; 563(1-3):216-23. DOI: 10.1016/j.ejphar.2007.01.070. View

5.
Jeong H, Pokharel Y, Han E, Kang K . Induction of cyclooxygenase-2 by ginsenoside Rd via activation of CCAAT-enhancer binding proteins and cyclic AMP response binding protein. Biochem Biophys Res Commun. 2007; 359(1):51-6. DOI: 10.1016/j.bbrc.2007.05.034. View